Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

297 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J, Shah K, Piguet V, Soung J. Reich K, et al. Among authors: bewley a. J Eur Acad Dermatol Venereol. 2017 Mar;31(3):507-517. doi: 10.1111/jdv.14015. Epub 2016 Dec 19. J Eur Acad Dermatol Venereol. 2017. PMID: 27768242 Free PMC article. Clinical Trial.
What is new in topical therapy for psoriasis?
Reich K, Bewley A. Reich K, et al. Among authors: bewley a. J Eur Acad Dermatol Venereol. 2011 Jun;25 Suppl 4:15-20. doi: 10.1111/j.1468-3083.2011.04061.x. J Eur Acad Dermatol Venereol. 2011. PMID: 21507079
Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study.
Layton AM, Schaller M, Homey B, Hofmann MA, Bewley AP, Lehmann P, Nohlgård C, Sarwer DB, Kerrouche N, Ma YM. Layton AM, et al. Among authors: bewley ap. J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2405-10. doi: 10.1111/jdv.13305. Epub 2015 Sep 28. J Eur Acad Dermatol Venereol. 2015. PMID: 26416154 Free PMC article. Clinical Trial.
Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Reich K, Gooderham M, Bewley A, Green L, Soung J, Petric R, Marcsisin J, Cirulli J, Chen R, Piguet V. Reich K, et al. Among authors: bewley a. J Eur Acad Dermatol Venereol. 2018 Mar;32(3):397-402. doi: 10.1111/jdv.14738. Epub 2018 Jan 29. J Eur Acad Dermatol Venereol. 2018. PMID: 29220542 Free PMC article. Clinical Trial.
Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey.
Armstrong A, Jarvis S, Boehncke WH, Rajagopalan M, Fernández-Peñas P, Romiti R, Bewley A, Vaid B, Huneault L, Fox T, Sodha M, Warren RB. Armstrong A, et al. Among authors: bewley a. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2200-2207. doi: 10.1111/jdv.15065. Epub 2018 Jul 31. J Eur Acad Dermatol Venereol. 2018. PMID: 29730888
Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison.
Bewley AP, Shear NH, Calzavara-Pinton PG, Hansen JB, Nyeland ME, Signorovitch J. Bewley AP, et al. J Eur Acad Dermatol Venereol. 2019 Jun;33(6):1107-1115. doi: 10.1111/jdv.15369. Epub 2019 Mar 19. J Eur Acad Dermatol Venereol. 2019. PMID: 30472749 Free PMC article.
A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).
Seneschal J, Lacour JP, Bewley A, Faurby M, Paul C, Pellacani G, De Simone C, Horne L, Sohrt A, Augustin M, Hammond E, Reich K. Seneschal J, et al. Among authors: bewley a. J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2566-2573. doi: 10.1111/jdv.16568. Epub 2020 Jun 8. J Eur Acad Dermatol Venereol. 2020. PMID: 32364296 Free PMC article.
297 results